A German Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Type 2 Diabetes Patients.

Inclusion Criteria: * Existence of a signed Informed Consent form (before any study procedure) * Diagnosed Type 2 diabetes mellitus * Age =18 years * Insulin therapy for =6 months: BOT, SIT, CT or ICT * HbA1c =7.5% within the last 6 weeks before study visit 1 (patient's inclusion) * Longer-term diabetes care by the trial site (at least for the duration of the 12-month study participation) * General practitioner is the primary practitioner in the diabetes care of the patient * Insured by the statutory health insurance (GKV) as a statutory or voluntarily insured member or as a family co-insured member * Willing and able to participate in the study and to follow the study procedures, among other things sufficient command of the German language, spoken and written Exclusion Criteria: * Diabetes treatment by insulin pump therapy (CSII) * Experience with the use of special software for systematic processing of SMBG data, e.g. the Accu-Chek® Smart Pix System/Software, the Accu-Chek® 360° Software and/or the Diabetes Software DIABASS * Presence of terminal renal failure / dialysis and/or a loss of sight or a tumor illness * Chronic use of steroids in adrenal suppressant doses, of other immuno-modulatory drugs or chemotherapy * Known alcohol, drug and medication abuse * Known metabolic disorders and/or disorders or therapies that could lead to or have led to wrong measured results (e.g. with the blood glucose measurement) * Existing pregnancy, breast-feeding or plan to become pregnant during study participation * Physical illness and/or psychological disorder with the result that the patient cannot implement the medical treatment recommendations independently * Dependency relationship to the sponsor or to the investigator, e.g. as a professional colleague or family member